Acuta Capital Partners, LLC Assembly Biosciences, Inc. Transaction History

Acuta Capital Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$8.36 - $23.81 $1.1 Million - $3.13 Million	-131,500 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$9.83 - $14.82 $260,495 - $392,730	-26,500 Reduced 16.77%	131,500 $1.29 Million
Q2 2019 Aug 14, 2019	SELL	$12.9 - $20.8 $7.77 Million - $12.5 Million	-602,500 Reduced 79.22%	158,000 $2.13 Million
Q1 2019 May 14, 2019	BUY	$17.7 - $24.93 $743,400 - $1.05 Million	42,000 Added 5.85%	760,500 $15 Million
Q4 2018 Feb 14, 2019	SELL	$19.05 - $36.45 $4.03 Million - $7.71 Million	-211,500 Reduced 22.74%	718,500 $16.3 Million
Q3 2018 Nov 07, 2018	SELL	$34.41 - $44.23 $7.98 Million - $10.3 Million	-232,000 Reduced 19.97%	930,000 $34.5 Million
Q2 2018 Aug 15, 2018	BUY	$39.21 - $50.29 $1.84 Million - $2.36 Million	47,000 Added 4.22%	1,162,000 $45.6 Million
Q1 2018 May 15, 2018	BUY	$41.7 - $64.16 $1.16 Million - $1.79 Million	27,896 Added 2.57%	1,115,000 $54.8 Million
Q4 2017 Feb 14, 2018	BUY	$28.58 - $49.91 $2.49 Million - $4.35 Million	87,104 Added 8.71%	1,087,104 $49.2 Million
Q3 2017 Nov 14, 2017	BUY	$23.08 - $34.92 $23.1 Million - $34.9 Million	1,000,000	1,000,000 $34.9 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $822M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.